News

HEATON Company launched the first generic bortezomib in Europe

Prague, 17 December 2015

One of the most interesting molecules in the oncology is the active substance bortezomib. Bortezomib is the first proteasome inhibitor used in clinical praxis.

Unlike other anti-cancer therapies the mechanism of action of bortezomib is completely different. Bortezomib has strong reversible and specific inhibitory activity against proteasome, multicatalytic enzyme complex that plays a crucial role in the management of proteins controlling the development of the cell cycle and consecutively apoptosis processes. The efficacy of bortezomib was proved in several preclinical studies in vitro and in vivo, when efficacy was gradually proven in myeloma cell lines, non-Hodgkin malignant lymphoma, tumours of pancreas, prostate, ovary, head and neck, or chronic lymphocytic leukaemia.

Bortezomib advantage is the possibility of combination with other conventional drugs, and its favourable safety profile. Rapid onset of action with high efficiency represents a significant benefit to patients. HEATON Company launched the first generic bortezomib in Europe. This product is available in form 3.5 mg powder for solution for injection for intravenous or subcutaneous application. On the Czech market is our bortezomib available from 1 October 2015, currently is administered to patients at oncology clinics
- University Hospital Plzeň, Czech Republic
- University Hospital Brno, Czech Republic
- University Hospital Ostrava, Czech Republic

This medicine is available from 1 December 2015 in the Slovak Republic. In both countries, the medicine is available in the distribution network and is fully covered by public health insurance. In January 2016 is expected launch of this product on the Romanian market.

In Czech and Slovak Republic is bortezomib indicated for monotherapy or combination with pegylated liposomal doxorubicin or dexamethasone or with melphalan and prednisone for the treatment of adult patients with progressive multiple myeloma in different stages of this disease. On the Czech market is product with bortezomib available in form 3.5 mg powder for solution for injection for intravenous or subcutaneous application. Product should not be given by other routes. Intrathecal administration has resulted in death.

If you are interested in more information on this product, please, visit section “Our products/ Prescription drugs“ or contact us at This email address is being protected from spambots. You need JavaScript enabled to view it. .